FDA News

MARCH 8, 2024

FDA Approves Wegovy for Cardiovascular Risk Reduction

By PPN Staff

The FDA approved semaglutide (Wegovy, Novo Nordisk) for lowering cardiovascular death, heart attack and stroke risk in overweight or obese adults who do not have diabetes.

To read the full story, Log in or Sign up for a Free Account

First Name

Last Name

Organization/Institution

State

NPI	Name	Organization/ Institution	State	Zip Code	Taxonomy	Credential	Select